CC BY-NC-ND 4.0 · Avicenna J Med 2013; 03(03): 68-72
DOI: 10.4103/2231-0770.118462

Combination of inflammatory and amlodipine induced gingival overgrowth in a patient with cardiovascular disease

Mohan Kumar Pasupuleti
Department of Periodontics, St. Joseph Dental College, Eluru, Andhra Pradesh, India
S. V. V. S. Musalaiah
Department of Periodontics, St. Joseph Dental College, Eluru, Andhra Pradesh, India
M Nagasree
Department of Periodontics, St. Joseph Dental College, Eluru, Andhra Pradesh, India
P Aravind Kumar
Department of Periodontics, St. Joseph Dental College, Eluru, Andhra Pradesh, India
› Author Affiliations


Gingival overgrowth (GO) is among one of the most important clinical features of gingival pathology frequently seen in periodontal clinic. Amlodipine is a comparatively new calcium channel blocker and is being used with increasing frequency in the management of hypertension and angina. A 48-year-old Indian woman who was on amlodipine for 3 years for hypertension reported to the department of periodontics with the complaint of swollen, un esthetic gums. The patient developed GO 6 months before her first visit to dental hospital. She developed GO very rapidly due to the increase in amlodipine dose due to the severe angina attack 6 months before and due to the use of cholesterol (CHO) lowering drug. The main aim of the case report is to study the severity of amlodipine induced GO in a patient with cardiovascular disease (CVD) and to identify the role of subgingival microorganisms on inflammatory gingival enlargement in the same patient. The severity and rapidity of gingival enlargement in this report could have been triggered by doubling the dose of amlodipine and concomitant use of CHO lowering drug.

Publication History

Article published online:
09 August 2021

© 2013. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

  • References

  • 1 Newman MG, Takei HH, Klokkevold PR, Carranza FA. Text book of clinical Periodontology. 11 th ed. Elsevier; p. 373-88.
  • 2 Rees TD, Levine RA. Systemic drugs as a risk factor for periodontal disease initiation and progression. Compend Contin Educ Dent 1995;16:20-42.
  • 3 Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study. J Periodontol 1999;70:63-7.
  • 4 Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-75.
  • 5 Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000 1999;21:176-96.
  • 6 Miranda J, Brunet L, Roset P, Berini L, Farre M, Mendieta C. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol 2001;72:605-11.
  • 7 Ramon Y, Behar S, Kishon Y, Engelberg IS. Gingival hyperplasia caused by nifedipine- a preliminary report. Int J Cardiol 1984;5:195-206.
  • 8 Barak S, Engelberg IS, Hiss Z. Gingival hyperplasia caused by nifedipine: Histopathologic findings. J Periodontol 1987;58:639-42.
  • 9 Fattore L, Stablein M, Bredfeldt G, Semla T, Moran M, Doherty-Greenberg JM. Gingival hyperplasia: A side effect of nifedipine and diltiazem. Spec Care Dentist 1991;11:107-9.
  • 10 Steel RM, Schuna AA, Schreilber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994;120:663-4.
  • 11 Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453-6.
  • 12 Meisel P, Schwahn C, John U, Kroemer HK, Kocher T. Calcium antagonists and deep gingival pockets in the population-based SHIP study. Br J Clin Pharmacol 2005;60:552-9.
  • 13 Friedewald VE, Kornman KS, Beck JD, Genco R, Goldfine A, Libby P, et al. American Journal of Cardiology; Journal of Periodontology. The American Journal of Cardiology and Journal of Periodontology editors′ consensus: Periodontitis and atherosclerotic cardiovascular disease. J Periodontol 2009;80:1021-32.
  • 14 Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77.
  • 15 Smitha K. Amlodipine-induced gingival overgrowth in a patient with uncontrolled type 2 diabetes mellitus with hypercholesterolemia: A case report. Clinical Advances in Periodontics. Vol. 2, No. 2, 2012.
  • 16 Ellis JS, Seymour RA, Robertson P, Butler TJ, Thomason JM. Photographic scoring of gingival overgrowth. J Clin Periodontol 2001;28:81-5.
  • 17 Boltchi FE, Rees TD, Iacopino AM. Cyclosporine A - induced gingival overgrowth: A comprehensive review. Quintessence Int 1999;30:775-83.
  • 18 Meller AT, Rumjanek VM, Sansone C, Allodi S. Oral mucosa alterations induced by cyclosporin in mice: Morphological features. J Periodontal Res 2002;37:412-5.
  • 19 Triveni MG, Rudrakshi C, Mehta DS. Amlodipine induced gingival overgrowth. J Indian Soc Periodontal 2009;13:160-3.
  • 20 Shouda J, Nakamoto H, Sugahara S, Okada H, Suzuki H Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients. J Clin Periodontal 2004;31:126-31.
  • 21 Nakou M, Kamma JJ, Andronikaki A, Mitsis F. Subgingival microflora associated with nifedipine-induced gingival overgrowth. J Periodontol 1998;69:664-9.
  • 22 Li X, Luan Q, Wang X, Sha Y, He L, Cao C, et al. Nifedipine intake increases the risk for periodontal destruction in subjects with type 2 diabetes mellitus. J Periodontol 2008;79:2054-9.
  • 23 Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowth. Aust Dent J 1999;44:219-32.